The majority of people with diabetes live in low- and middle-income countries.1 Access to reliable and affordable supplies of insulin is a challenge for many. In fact, it is estimated that 50 million people lack access to insulin worldwide.2
Novo Nordisk has addressed this challenge since we introduced our Differential Pricing Policy for Least Developed Countries (LDCs) in 2001. Under this policy we offered human insulin in LDCs at a price that does not exceed 20% of the average realised price for Europe, the US, Canada and Japan.
Our continued commitment to having a low-cost insulin in our product portfolio and to producing and making human insulin available for years to come, is formulated in our Access to Insulin Commitment which in 2016 was updated to include other low-income countries and selected humanitarian organisations.
As of 2019, the guarantee is expanded to include 29 middle-income countries as defined by the World Bank. This means that a total of 78 countries, home of 124 million people with diabetes1, as well as selected humanitarian organisations, can benefit from this guarantee.
The commitment builds on the following principles:
In 2018, the average selling price was USD 2.89 per vial. As a result, an estimated 0.3 million people were treated with insulin for on average 12 cents per day. Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated 5 million people in 2018.
1. International Diabetes Federation. IDF Diabetes Atlas, 8th edition, 2017
2. ACCISS. Fact Sheet on Inequities and Inefficiencies in the global insulin market. Amsterdam: Health Action International; 2015. Retrieved from: http://haiweb.org/wp-content/uploads/2015/11/ACCISS-Fact-Sheet-1-Inequalities-in-Insulin-Market.pdf.Accessed September 2016